logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Journal Article
|Research

Immunogenicity and protection from a single dose of internationally available killed oral cholera vaccine: a systematic review and meta-analysis

Lopez AMZ, Deen JL, Azman AS, Luguero FJ, Kanungo S, Dutta S, von Seidlein L, Sack DA
Download

Similar Content
Loading...
Loading...
Loading...
Immunogenicity and protection from a single dose of internationally available killed oral cholera vaccine: a systematic review and meta-analysis | Journal Article / Research | MSF Science Portal
Abstract
In addition to improved water supply and sanitation, the two-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efficacy and effectiveness) conferred by a single OCV dose against cholera. The meta-analysis showed an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, after an OCV first dose. The estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufficient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggests otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.

Subject Area

vaccinationoutbreakscholera

Languages

English
DOI
10.1093/cid/cix1039
Published Date
21 Nov 2017
PubMed ID
29177437
Journal
Clinical Infectious Diseases
Volume | Issue | Pages
Volume 66, Issue 12, Pages 1960-1971
Issue Date
2017-11-21
Dimensions Badge